Home Newsfeeds Mizuho Maintains Neutral on Splunk, Lowers Price Target to $110

Mizuho Maintains Neutral on Splunk, Lowers Price Target to $110

Mizuho analyst Gregg Moskowitz maintains Splunk (NASDAQ:SPLK) with a Neutral and lowers the price target from $115 to $110.

byBenzinga Newsdesk

September 27, 2022

1 minute read

Mizuho analyst Gregg Moskowitz maintains Splunk (NASDAQ:SPLK) with a Neutral and lowers the price target from $115 to $110.

Analyst Cautiously Optimistic On Alignment Healthcare, Assesses Journey to Profitability Of Medicare Advantage Firm

By Vandana Singh

October 12, 2:31 PM

Stephens initiated coverage on Alignment Healthcare Inc (NASDAQ: ALHC), saying it offers growth-oriented small-cap investors pure-play exposure to Medicare Advantage (MA), a catalyst for sustained growth in Managed Care.

ALHC

National Institutes of Health’s Long COVID Initiative To Assess Pfizer’s Antiviral Pill As Potential Treatment

By Vandana Singh

October 28, 8:39 AM

The National Institutes of Health's $1 billion RECOVER Initiative has decided to study Pfizer Inc's (NYSE: PFE) antiviral drug Paxlovid as a potential treatment for long COVID.

PFE

Top 2 Energy Stocks That Are Preparing To Pump In April

By Avi Kapoor

April 1, 7:16 AM

The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.

CRT

Turning 15 Years Of Imprisonment Into Cannabis Advocacy, Luke Scarmazzo Shares His Vision

By Joana Scopel

July 17, 3:49 PM

"It’s been a surreal kind of whirlwind," said Luke Scarmazzo, brand & justice ambassador for Glass House Brands Inc. (OTCQX: GLASF), 67 days after serving a 15-year prison sentence for cannabis-related offenses. Where?

GLASF

Mizuho Maintains Neutral on Splunk, Lowers Price Target to $110

Related Posts

Analyst Cautiously Optimistic On Alignment Healthcare, Assesses Journey to Profitability Of Medicare Advantage Firm

National Institutes of Health’s Long COVID Initiative To Assess Pfizer’s Antiviral Pill As Potential Treatment

Top 2 Energy Stocks That Are Preparing To Pump In April

Turning 15 Years Of Imprisonment Into Cannabis Advocacy, Luke Scarmazzo Shares His Vision